We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -256.00 | -2.14% | 11,708.00 | 11,710.00 | 11,716.00 | 11,908.00 | 11,678.00 | 11,844.00 | 2,989,208 | 16:35:08 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 54.07B | 7.04B | 4.5371 | 25.82 | 185.51B |
From Feb 2020 to Feb 2025
By Razak Musah Baba
LONDON--Biopharmaceutical firm AstraZeneca PLC (AZN.LN) said Tuesday it is selling the U.S. rights to its generic high blood pressure drug Toprol-XL to Aralez Pharmaceuticals Trading DAC for an initial payment of $175 million.
As part of the agreement, Aralez will pay the U.K.-based drugmaker to acquire the rights to Toprol-XL tablets in the U.S. and the authorized generic medicine marketed by Par Pharmaceuticals.
Aralez will also pay AstraZeneca up to $48 million in milestone and sales-related payments, as well as mid-teen percentage royalties on sales.
Toprol-XL is a beta-blocker medicine for the control of hypertension, angina and heart failure. It was first approved in the U.S. in 1992.
AstraZeneca said it will continue to manufacture and supply Toprol-XL and the authorized generic medicine to Aralez.
Aralez Pharmaceuticals Trading DAC is a unit of Aralez Pharmaceuticals Inc. (ARLZ), a global specialty pharmaceutical company.
Write to Razak Musah Baba at razak.baba@wsj.com; Twitter: @Raztweet
(END) Dow Jones Newswires
October 04, 2016 03:03 ET (07:03 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
